Navigation Links
DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3)

60760258

A replay of the webcast will be available through May 17, 2007 and may be accessed by dialing 1-888-286-8010. International callers should dial 617-801-6888. The replay passcode for all callers is 25344900. The webcast will be archived on the Dyax website for an indefinite period of time.

About Dyax

Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development.

Dyax's lead product candidate is DX-88, a recombinant small protein that is currently in clinical trials for its therapeutic potential in two separate indications. Dyax has successfully completed three Phase 2 trials and a Phase 3 trial of DX-88 for the treatment of hereditary angioedema (HAE). A confirmatory study, known as EDEMA4, is planned and expected to begin in the first quarter of 2007. DX-88 has orphan drug designation in the U.S. and E.U., as well as Fast Track designation in the U.S. for the treatment of acute attacks of HAE.

Additionally, Dyax has successfully completed a Phase 1/2 trial of DX-88 for the prevention of blood loss during on-pump coronary artery bypass graft (CABG) procedures. Dyax is initiating a Phase 2 trial for further development of DX-88 in on-pump cardiothoracic surgery (CTS), including CABG and heart valve replacement or repair procedures.

Dyax identified DX-88 and other compounds in its pipeline using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue-generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents.

Dyax is headquartered in Cambridge, Massachusett
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema
3. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
4. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
7. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
8. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
11. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation

Post Your Comments:
(Date:11/9/2009)...FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SH...any, today announced the availability of INTUNIV...armacies across the United States for the treatmen...DHD ) in children and adolescents ages 6 to 17. ...s the first and only nonscheduled alpha-2A recepto...
(Date:11/9/2009)...all/ -- PAREXEL International Corporation (Nasdaq:...ces provider, today announced that it has enhanced...linical development through an alliance with Morta...butes electrocardiogram (ECG) devices and related ...trument,s Surveyor Telemetry Central System to sup...
(Date:11/7/2009)...wire/ -- Most patients with hereditary angioedema ...ing HAE attack giving the patients sufficient time...associated with that attack, according to survey f...ge of Allergy, Asthma & Immunology (ACAAI) Ann... fatigue and nausea, which occur frequently before...
Breaking Medicine Technology:Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 2Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 3Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 4Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 5Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 6Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Now Available in Pharmacies Nationwide 7PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 2PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 3PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 4PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 5Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 2Prodromal Symptoms Warn of Hereditary Angioedema Attacks, Give Patients Time to Start Therapy and Decrease Morbidity 3Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6 2009 14348 1Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6 2009 14348 2Misonix Inc Announces the Sale of Sonora Medical Systems for 248 Million 5218 1Misonix Inc Announces the Sale of Sonora Medical Systems for 248 Million 5218 2Misonix Inc Announces the Sale of Sonora Medical Systems for 248 Million 5218 3Facilitation Payments Seen as Problematic by Many Companies 5215 1Facilitation Payments Seen as Problematic by Many Companies 5215 2Facilitation Payments Seen as Problematic by Many Companies 5215 3Facilitation Payments Seen as Problematic by Many Companies 5215 4
...PHIS, Tenn., Sept. 10 As a surgeon and clinical,i...firsthand about the,growing number of patients con...Infections. He was also keenly aware that infectio...tem into schools, gyms, prisons and,retirement hom...13,510 admissions at an,accredited 450-bed regiona...
...TIN, Texas, Sept. 10 The first-ever human,clinica...bal tea was,recently conducted, testing whether th...r disease., The new trial also generated the firs... environment, scientifically showing that,short-te...r and kidneys,while keeping various blood paramete...
Other Medicine Technology:Doctor Declares War on Hospital Infections, Patents MRSA-Killing Machine 2Clinical Trial Shows Cardiovascular Benefits of Rooibos, Popular Antioxidant Herbal Tea from South Africa 2Clinical Trial Shows Cardiovascular Benefits of Rooibos, Popular Antioxidant Herbal Tea from South Africa 3Clinical Trial Shows Cardiovascular Benefits of Rooibos, Popular Antioxidant Herbal Tea from South Africa 4Clinical Trial Shows Cardiovascular Benefits of Rooibos, Popular Antioxidant Herbal Tea from South Africa 5
(Date:11/9/2009)...out among thousands of people has shown a clear co...s, leading to osteoporosis and fractures. , Thi...esearchers, Prof. Raz Yirmiya, head of the Brain a...f the Bone Laboratory. They further revealed that ...is particularly strong among young women. , Oste...
(Date:11/9/2009)...Nutrition announced today the acquisition of App T... subsidiary of Natural Nutrition. Natural Nutriti...he company will focus its efforts on the business ...ing mobile application market places throughout em...d on multi platform apps designed to run on device...
(Date:11/9/2009)...r development of scientists and science trainees w...ical medicine, AAAS, Science Careers, and Science ...called CTSciNet, the Clinical and Translational Sc... November 6, 2009 -- Launched October 20 by Scienc...CTSciNet is an online community for people pursui...
(Date:11/9/2009)...rm Bill, The Affordable Health Care for American A...urday Night, and Is Expected to Be Signed into Law...h Absolute Confidence. ERISAclaim.com Announced th...fically for the Compliance with the New Federal He... Hanover Park, IL (PRWEB) November 9, 20...
(Date:11/9/2009)...orporation announces that their design, production... Minneapolis, MN (Vocus) November 9, ...g manufacturer of miniature high-rel connectors, a...ems have been certified to the ISO 9001:2000 (w/de...ystem Standard., , ,The company,s entire quality s...
Breaking Medicine News(10 mins):Health News:Connection between depression and osteoporosis detailed by Hebrew University researchers 2Health News:Social Network for Translational Scientists Launched 2Health News:Social Network for Translational Scientists Launched 3Health News:Social Network for Translational Scientists Launched 4Health News:The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim.com 2Health News:The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim.com 3Health News:The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim.com 4Health News:The New Healthcare Reform Bill Passed by The Congress Prompted The New Claim Specialist Certification Class from ERISAclaim.com 5Health News:Omnetics Connector Corporation Achieves AS9100 Certification 2
...alth,programs in Michigan, Ohio, and Indiana are e...e Delta Dental Foundation,s third annual Community...ay by Nancy E. Hostetler,senior vice president of ...ize oral health initiatives.,Special consideration...
...g disorder cuts the danger, one expert says , ...rupted nighttime breathing of sleep apnea appears ...ers report. , Earlier studies have linked sleep ap...the risk is present among all people with obstruct...
...varies greatly for the treatment of men with early...d category of health care facility, suggesting the... standard treatment protocols, according to a new ...est that there is much to do before quality improv...
...y of Pennsylvania School of Medicine have discover... maintain the proper level of bile in the liver. F...at diseases that involve the regulation of bile sa... through ducts to the small intestine where it hel...
...t renowned for enhancing athletic performance and ...s in patients with chronic obstructive pulmonary d...mized, placebo-controlled, double-blind study prov...ence to suggest Cr uptake into muscles [in COPD pa...
...cond year in a row, is giving away $1 million in d...o need it the most. , Nor...year in a row, http://www.youtube.com/watch?v=VgH...away $1 million in discount pharmacy cards to unin...
Other Medicine News:Health News:Delta Dental Foundation Calls for Applicants for Annual Community Mini-Grant Program 2Health News:Sleep Apnea Boosts Death Risk 2Health News:Sleep Apnea Boosts Death Risk 3Health News:Disparities in prostate cancer treatment suggest ways to improve care 2Health News:Penn researchers find a new role for a 'Foxy Old Gene' 2Health News:No substitute for hard work: Creatine supplementation does not improve exercise outcomes in COPD 2Health News:Vertrue Incorporated and Feed The Children Join Forces to Give Away $1 Million in Aid to Families in Need 2Health News:Vertrue Incorporated and Feed The Children Join Forces to Give Away $1 Million in Aid to Families in Need 3Health News:Vertrue Incorporated and Feed The Children Join Forces to Give Away $1 Million in Aid to Families in Need 4
...r the control of glucose metabolism. It is synthe...s the precursor, proinsulin, which is processed to... equimolar amounts into the portal circulation. T...ypeptide chains, the A-chain and B-chain (21 and 3...
...reatic -cell function is not only of use in the pr...y of diabetes mellitus, but is also relevant in cl...f treatment. Peripheral insulin levels cannot be u...and variable uptake from the portal circulation in...
...eimmunoassay for the quantitation of 25-OH D and o...Calibrators, controls and samples are diluted with...incubated in microtitre wells which are coated wit...ours at room temperature before aspiration and was...
...r the control of glucose metabolism. It is synthe...s the precursor, proinsulin, which is processed to... equimolar amounts into the portal circulation. T...ypeptide chains, the A-chain and B-chain (21 and 3...
Medicine Products: